2024-03-08 17:15:31 ET
Summary
- AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024.
- The company has improved revenue guidance for 2024, after guidance beating 2023 numbers. It also sustains a healthy EPS guidance.
- Recently received approvals in the U.S. and China can prop up revenue growth, and its continued dividend payouts and attractive forward P/E can positively impact the stock price.
Oncology-focused pharmaceuticals company AstraZeneca PLC ( AZN ) has had an underwhelming past year at the stock markets, with just a 3% price rise. However, the limited price change detracts from the fundamental positives of the stock. Here, I look at 5 aspects that set it apart and can provide impetus for price upside in 2024....
Read the full article on Seeking Alpha
For further details see:
5 Reasons AstraZeneca Stock Can Rise In 2024